At a glance
- Atosiban is not an FDA-approved drug: Drugs@FDA has no record of it.
- PubMed lists 578 publications mentioning it, including 54 randomized controlled trials and 172 animal-only studies.
- ClinicalTrials.gov lists 23 registered studies testing it (3 active).
- FDA's adverse event system (FAERS) holds 830 reports mentioning it; 823 classified as serious. Reports do not prove causation.
Research topics
Most frequent MeSH subject headings in the latest PubMed records (English, as indexed).
Regulatory status
Drugs@FDA applications
No application found in Drugs@FDA, FDA's database of approved drugs.
Source: Drugs@FDA (openFDA) · verified October 30, 2026 · API query
FDA compounding safety list
Not on FDA's list of bulk drug substances that may present significant safety risks in compounding.
Source: FDA.gov — Category 2 bulk drug substances · verified October 30, 2026
Removal of a substance from a regulatory list does not mean it has been approved. A "research use only" label does not make a product safe or legal for human use.
Scientific publications
Counts are PubMed records that mention the peptide in the title or abstract. Categories overlap, and a mention is not the same as testing the peptide as a treatment. Each number opens the exact PubMed search. Effects seen in laboratory or animal studies may not occur in humans. A registered clinical trial does not show that a substance is effective or safe.
Latest publications
- Oxytocin Signalling in Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia and Overactive Bladder Syndrome: A Narrative Review.
- Atosiban versus nifedipine for the management of preterm labor: a systematic review and meta-analysis of randomized controlled trials.
- Discovery of an antagonist nanobody targeting the oxytocin receptor with tocolytic effect in mice.
- Characterization of cisternal, alveolar, and residual milk fractions in dromedary (Camelus dromedarius) and Bactrian camels (Camelus bactrianus).
- Pharmacological characterization of neuromodulatory systems involved in biased social interaction toward stressed conspecifics in male rats.
- Drug repurposing identifies candidate uterus-selective tocolytics for preterm labor.
- Nifedipine-associated maternal oxygen desaturation in an IVF twin pregnancy complicated by preterm premature rupture of membranes: a case report.
- Atosiban-Associated Non-cardiogenic Pulmonary Edema in a Dichorionic Diamniotic Twin Pregnancy: A Case Report.
- Role of the tail of the ventral tegmental area in the regulation of maternal behaviour: a pharmacological study in postpartum rats.
- Delicate Balance of Intra- and Inter-Molecular Entropic Effects in S-S Peptide Cyclization.
Source: PubMed (NCBI) · verified October 30, 2026
Clinical trials
- Registered
- 23
- Active
- 3
- With posted results
- 2
Conditions studied
Show 13 more studies
All 23 studies on ClinicalTrials.gov ↗
Source: ClinicalTrials.gov · verified October 30, 2026
Adverse event reports
- Reports
- 830
- Serious
- 823
- With death outcome
- 25
Most reported reactions
Adverse event reports do not prove that the substance caused these effects. Side effects not listed here may still occur. Reaction terms are MedDRA terms as reported to FAERS.
Source: FDA FAERS (FAERS data as of July 30, 2026) · verified October 30, 2026 · API query
Change history
No changes since monitoring began on October 30, 2026.